D. Jarrard
Molecular Biology · 2010–2018
A researcher in the Science corpus: 3 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 14 citations into it
- Physiology — 14 citations into it
Whom D. Jarrard trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Campisi (in Physiology)
- F. d’Adda di Fagagna (in Physiology)
Papers from D. Jarrard's perspective
Ordered by how strongly the researchers D. Jarrard trusts endorse each paper. Same corpus, a different order for every researcher.
- Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging (Proceedings of the National Academy of Sciences of the United States of America)
- Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. (Cell)
- Chemokine signaling via the CXCR2 receptor reinforces senescence. (Cell)
- Tumour biology: Senescence in premalignant tumours (Nature)
- Living on a break: cellular senescence as a DNA-damage response (Nature Reviews. Cancer)
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
- Reversal of human cellular senescence: roles of the p53 and p16 pathways (EMBO Journal)
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas (Nature)
- BRAFE600-associated senescence-like cell cycle arrest of human naevi (Nature)
- Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. (Cell)
Their papers
- Therapy-induced senescence in cancer. (2010) — 768 citations
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. (2018) — 911 citations
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (2015) — 2,587 citations